|
|
|
Abstract Objective To explore whether AMP， a flavonol mainly found in Ampelopsis grossedentata， induces cell growth inhibition by suppressing glycolysis through Akt-mTOR/PKM2 pathway in breast cancer cells. Methods After MCF-7 and MDA- MB-231 breast cancer cells treated with 20， 40， 60 and 80μmol/L AMP for 24h， cell viability was assessed by CCK-8 assay， glucose uptake assay was performed using 2-NBDG， lactate levels were measured using the colorimetric lactate assay kit and the protein expressions were assessed by Western blot. Results AMP treatment could inhibit cell viability in MCF-7 and MDA- MB-231 breast cancer cells in dose-dependent manners. The further experiments exhibited that AMP successfully blocked cell glycolysis by inhibiting the level of glucose uptake and the production of lactic acid， decreased the level of glycolysis-related proteins pyruvate kinase M2 (PKM2)， glucose transporter1 (GLUT1) and lactate dehydrogenase A (LDHA)， and also inactivated the Akt-mTOR pathway by down-regulation of p-Akt、p-mTOR、p-p70S6K expressions. However， Akt-mTOR pathway inducer IGF-1 treatment significantly attenuated AMP- induced above mentioned results. Conclusion AMP suppressed breast cancer cell growth and glycolysis through inhibiting Akt-mTOR/PKM2 pathway， and may provide a potential therapeutic target for breast cancer treatment.
|
|
|
|
|
|
1.Qureshi AS， Ali S. Review: Warburg effect and renal cancer caused by errs in fumarate hydratase encoding gene. Pak J Pharm Sci. 2019；32(2):743-749.
2.Liu Y， Zhang Z， Wang J， et al. Metabolic reprogramming results in abnormal glycolysis in gastric cancer: a review. Onco Targets Ther. 2019；12:1195-1204.
3.Zheng YL， Li L， Jia YX， et al. LINC01554-mediated glucose metabolism reprogramming suppresses tumorigenicity in hepatocellular carcinoma via downregulating PKM2 expression and inhibiting Akt/mTOR signaling pathway.Theranostics. 2019；9(3):796-810.
4.Siddiqui FA， Prakasam G， Chattopadhyay S， et al. Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition. Sci Rep. 2018；8(1):8323-8331.
5.Tao T， Su Q， Xu S， et al. Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis. J Cell Physiol. 2019；234(3):3088-3104.
6.Xiaoyu H， Yiru Y， Shuisheng S， et al. The mTOR pathway regulates PKM2 to affect glycolysis in esophageal squamous cell carcinoma. Technol Cancer Res Treat. 2018；17:1-10.
7.Luis C， Duarte F， Faria I， et al. Warburg effect inversion: adiposity shifts central primary metabolism in MCF-7 breast cancer cells. Life Sci. 2019；223:38-46.
8.Amin S， Yang P， Li Z. Pyruvate kinase M2: A multifarious enzyme in non-canonical localization to promote cancer progression. Biochim Biophys Acta Rev Cancer. 2019；1871(2):331-341.
9.Rossi M， Strikoudi P， Spei ME， et al. Flavonoids and bladder cancer risk. Cancer Causes Control. 2019；30(5):527-535.
10.Kashyap D， Garg VK， Tuli HS， et al. Fisetin and quercetin: promising flavonoids with chemopreventive potential.Biomolecules. 2019；9(5):174-175
11.Aslan E， Guler C， Adem S. In vitro effects of some flavonoids and phenolic acids on human pyruvate kinase isoenzyme M2. J Enzyme Inhib Med Chem. 2016；31(2):314-317.
12.Jia L， Huang S， Yin X， et al. Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction. Life Sci. 2018；208:123-130.
13.宁涛，巴一.肿瘤生长与转移的代谢基础.肿瘤代谢与营养电子杂志. 2017；4(4):371-375.
14.Zhou Y， Liang X， Chang H， et al. Ampelopsin-induced autophagy protects breast cancer cells from apoptosis through Akt-mTOR pathway via endoplasmic reticulum stress. Cancer Sci. 2014；105(10):1279-1287.
15.Zhu H， Wu J， Zhang W， et al. PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer. Sci Rep. 2016；6:30788-30798.
16.Ye G， Qin Y， Wang S， et al. Lamc1 promotes the Warburg effect in hepatocellular carcinoma cells by regulating PKM2 expression through AKT pathway. Cancer Biol Ther. 2019；20(5):711-719.
17.Pinheiro C， Granja S， Longatto-Filho A， et al. GLUT1 expression in pediatric adrenocortical tumors: a promising candidate to predict clinical behavior. Oncotarget. 2017；8(38):63835-63845.
18.Lin C， Xu X. YAP1-TEAD1-Glut1 axis dictates the oncogenic phenotypes of breast cancer cells by modulating glycolysis. Biomed Pharmacother. 2017；95:789-794.
19.Chen TY， Hsieh YT， Huang JM， et al. Determination of pyruvate metabolic fates modulates head and neck tumorigenesis.Neoplasia. 2019；21(7):641-652.
20.Wang H， Peng R， Chen X， et al. Effect of HK2， PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer.Oncol Lett. 2018；15(4):5553-5560.
21.Huang C， Huang YL， Wang CC， et al. Ampelopsins A and C induce apoptosis and metastasis through downregulating AxL， TYRO3， and FYN expressions in MDA-MB-231 breast cancer cells.J Agric Food Chem. 2019；67(10):2818-2830.
22.Ayuk SM， Abrahamse H. mTOR signaling pathway in cancer targets photodynamic therapy in vitro.Cells. 2019；8(5):431-443.
23.Bossler F， Hoppe-Seyler K， Hoppe-Seyler F. PI3K/akt/mtor signaling regulates the virus/host cell crosstalk in HPV-positive cervical cancer cells.Int J Mol Sci. 2019；20(9):2188-2199.
24.Cui XL， Li KJ， Ren HX， et al. Extract of Cycas revoluta Thunb. enhances the inhibitory effect of 5-uorouracil on gastric cancer cells through the AKT-mTOR pathway.World J Gastroenterol. 2019；25(15):1854-1864.
25.Chen YL， Lin HW， Sun NY， et al. Mtor inhibitors can enhance the anti-tumor effects of dna vaccines through modulating dendritic cell function in the tumor microenvironment.Cancers (Basel). 2019；11(5):617-626.
26.Yasumizu Y， Hongo H， Kosaka T， et al. PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer. Oncotarget. 2018；9(45):27698-27707.
27.Son JY， Yoon S， Tae IH， et al. Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways.Cancer Med. 2018； 7(10):5083-5095. |
|
|
